Fachliteratur Gastroenterologie: Neoplasien Pankreas

Fr | De

Feedback | Impressum | Sitemap

Keine Artikel ausgewählt!

Warenkorb

Sie sind hier: Fachliteratursuche » Pankreas » Neoplasie

17. September 2025

Abklärungen / Diagnostik

Therapien

Guidelines

Fortbildung

News / Journalscreening

Schrift:

Seite 1 von 2842


	Artikel 1 - 20 / 56827

	Changes in intestinal microbiota in patients with pancreatic cancer: a systematic review and meta-analysis. Front Microbiol Liang M, Liu Z, Zhang R, Yang JH, Wang XW, Zhang N. PMID: 40959217 [PubMed]
	Application of machine learning for prognostic modeling in unresectable pancreatic cancer treated with chemoradiotherapy. Front Oncol Xiao W, Yang B, Ke S. PMID: 40958868 [PubMed]
	Integrating intratumoral, peritumoral, and clinical features in an ultrasound-based radiomics model: contributions and synergies for predicting microvascular invasion in hepatocellular carcinoma. Front Oncol Fu H, Huang Y, Lu B, Yu J, Zhou D, Hou C, Xu L, Qian H. PMID: 40958856 [PubMed]
	Late-Onset Pancreatic Metastasis From Renal Cell Carcinoma Mimicking a Neuroendocrine Tumor: A Diagnostic Challenge and Literature Review. Cureus Jain M, Singh A, Kumar N, Mohindra S. PMID: 40955240 [PubMed]
	Slowly progressive type 1 diabetes and female sex as associated factors for pancreatic abnormalities on diagnostic imaging indicating precancerous potential. BMJ Open Diabetes Res Care Fukui T, Kobayashi T, Awata T, Ikegami H, Imagawa A, Oikawa Y, Osawa H, Kawasaki E, Kuwabara M, Kobayashi K, Katsuki T, Kanatsuna N, Kozawa J, Kodani N, Shimada A, Shimoda M, Takahashi K, Chujo D, Tsujimoto T, Tsuchiya K, Terasaki J, Nagasawa K, Noso S, Horie I, Yasuda K, Yasuda H, Hanafusa T, Kajio H, Japanese Type 1 Diabetes Database Study (TIDE-J). PMID: 40954045 [PubMed - indexed for MEDLINE]
	Bioactive compounds from marine algae in pancreatic cancer therapy: mechanistic insights into fucoidan and phlorotannins: a review. Med Oncol Prabhu N, Rajinikanth V, Narayanan M. PMID: 40952567 [PubMed - indexed for MEDLINE]
	Effect of HER3 Overexpression on Survival Outcomes in Pancreatic Cancer Patients: A Systematic Review and Meta-Analysis. Asian Pac J Cancer Prev Hassanzadeh Makoui M, Fekri S, Jafari Z, Hassanzadeh Makoui R, Ansari N, Shokrzadeh S. PMID: 40952271 [PubMed - indexed for MEDLINE]
	Comparison of therapeutic potential of macrophage- or mesenchymal stem cell-derived exosomes in pancreatic cancer: An updated review. World J Stem Cells Kacaroglu D, Gurbuz N. PMID: 40951713 [PubMed]
	Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial. Res Sq Park W, O'Connor C, Chou J, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Chatila W, Sivaprakasam K, Umeda S, Perry M, Varghese A, Yu K, Balogun F, Zervoudakis A, Katz S, Kim TH, Zhao K, Richards A, Lecomte N, Muldoon D, Karnoub E, Yang J, El-Dika I, Rao D, Smita J, Foote M, Sugarman R, Harding J, Epstein A, Kelsen D, Chalasani S, Keane F, Schoenfeld J, Singhal A, Diguglielmo E, Bandlamudi C, Song J, Ozkan HS, Hong J, Zhang H, Cardenas A, Lao M, Melchor J, Shah R, Kang W, Mazzoni F, Soares K, Donoghue M, Balachandran V, Schattner M, Santos E, Rolston V, Reyngold M, Wei A, Homsi R, Tipping M, Basturk O, Berger M, Do R, Jarnagin W, Riaz N, Pe'er D, Capanu M, Iacobuzio-Donahue C, O'Reilly E. PMID: 40951294 [PubMed]
	Enhanced antitumor efficacy of sorafenib and everolimus combination in pancreatic neuroendocrine neoplasms through mTOR inhibition. Transl Cancer Res Zheng H, Gao Y, Ye M, Bai J, Liu M, Long Q, Chen J, Qiang X, Tang Q. PMID: 40950667 [PubMed]
	Value of ZSCAN9 in the treatment and survival prediction of hepatocellular carcinoma: a bioinformatics study. Transl Cancer Res Jing S, Dong W, Zhan C. PMID: 40950662 [PubMed]
	Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival. J Gastrointest Oncol Elhariri A, Patel J, Mahadevia H, Modi K, Albelal D, Majeed U, Jones JC, Borad MJ, Tran NH, Rutenberg MS, Babiker H. PMID: 40950337 [PubMed]
	The incidence and risk factors of venous thromboembolism in patients with pancreatic cancer: a systematic review and meta-analysis. J Gastrointest Oncol Zhou X, Jiang Y, Xu H, Bai X, Lin S, Xu T, Liu S. PMID: 40950327 [PubMed]
	The role of inflammatory factors in the tumor microenvironment of pancreatic cancer. Front Immunol Yuan Y, Zhang H, Wang Z, Huang L, Kabacaoglu D, Zhang B, Song L, Ai J. PMID: 40948749 [PubMed - indexed for MEDLINE]
	A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study. Sci China Life Sci Xia F, Yan J, Liu X, Huang Z, Qiu Z, Zhang Q, Wu Z, Huang Z, Wei R, Lin L, Liu L, Han S, Yuan Y, Yin H, Xia G, Wan Y, Xiao S, Li J, Zhou G, Xia X, Sun H, Wang S, Zheng J, Gao H, Zheng J, Ren L, Mo A, Fu J, Ye L, Ruan S, Wang Y, Chen X, Cheng Q, Zhang B, Zhu P. PMID: 40947464 [PubMed - as supplied by publisher]
	Targeted protein degradation in pancreatic cancer: advances and challenges of PROTAC-based therapeutics. Bioorg Chem Huang M, Wei F, Cao J, Jiang H. PMID: 40946517 [PubMed - as supplied by publisher]
	Multi-drug pharmacotyping improves therapy prediction in pancreatic cancer organoids. Cancer Cell Int Wansch K, Pelzer U, Schneider F, Dölvers F, Kühn A, Dragomir MP, Ihlow J, Hilfenhaus G, Vecchione L, Felsenstein M, Ma D, Lerchbaumer M, Jürgensen C, Bahra M, Granada AE, Duwe G, Stintzing S, Keilholz U, Neumann CCM. PMID: 40946104 [PubMed]
	Polyamines in pancreatic cancer: reshaping the immunosuppressive tumor microenvironment. Cancer Lett Jiang S, Ren B, Ding C, Du C, Cao Z, Yang G, Huang H, Zhang T. PMID: 40945572 [PubMed - as supplied by publisher]
	KDM5C: A dual-edged epigenetic regulator in cancer biology-context-dependent roles and therapeutic implications. Biochem Pharmacol Tu FY, Liu YJ, Li X, Cao KF, Yu J, Wang R, Yang GJ, Chen J. PMID: 40945540 [PubMed - as supplied by publisher]
	Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial. Lancet Oncol Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, Bouwense SAW, Brouwer-Hol L, Bruynzeel AME, Busch OR, Coene PLO, van Eijck CHJ, de Groot JWB, Haberkorn BCM, de Hingh IHJT, Karsten TM, Kazemier G, van der Kolk MB, Liem MSL, Loosveld OJL, Luelmo SAC, Luyer MDP, Mekenkamp LJM, Mieog JSD, Nieuwenhuijs VB, Nuyttens JJME, Patijn GA, van Santvoort HC, Stommel MWJ, Versteijne E, de Vos-Geelen J, de Wilde RF, Zonderhuis BM, van der Holt B, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B, Dutch Pancreatic Cancer Group. PMID: 40945523 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 56827

Seite 1 von 2842



		Zeitfenster

Ironmedline

Das Fachportal für Eisenmangel >>

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung